Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
Lilly's Omvoh approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
Lilly's Omvoh demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
Lilly's Verzenio® prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
Lilly to present new clinical data for Verzenio and multiple novel pipeline programs at the 2025 European Society for Medical Oncology Annual Meeting
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lilly's Kisunla receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
U.S. FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
80 Mile PLC Secures 3 Strategic MOUs with Fortune 500 Energy Group, Ludoil, and JEnergy and moves to 100% of Ferrandina Biofuels Plant
Cotec Purchases Commercial Scale Salter Cyclone Multi-Gravity-Separator Unit to be Located at Corem Québec, Canada
